In the parent application for this supplement, R01CA123055, we described specific aims to determine (i) in which cell type(s) COX-2 must be expressed for skin cancer induction, using the DMB/TPA and UV-B protocols, and (ii) in which cell type(s) skin cancer induction can be modulated by COX-2 over expression. We generated """"""""floxed"""""""" Cox2 (Cox2flox) mice in which critical Cox2 exons are flanked by loxP sites and COX-2 conditional over expresser (COX-2 COE) transgenic mice in which the CAG promoter drives COX-2 protein expression. However, the CAG promoter is separated from the COX-2 coding region by a floxed transcription/translation STOP sequence in the COX-2 COE mouse. We planned to determine, by crossing Cox2flox mice with mice that express Cre recombinase in a tissue specific fashion, in which cell type(s) COX-2 must be expressed for skin cancer induction by DMBA/TPA and/or UV-B. When the Cox2 gene is deleted in skin epithelial cells (by crossing Cox2flox mice with Keratin14CreTg mice) DMBA/TPA skin tumor formation is extensively inhibited. In contrast - and surprisingly, we think - when the Cox2 gene is deleted in macrophage/monocytes (by crossing Cox2flox mice with LysMCreTg mice) skin tumor formation is increased, relative to littermate controls. COX-2 mediated prostaglandin (PG) formation in epithelial cells and in monocyte/macrophages has distinctly different roles in skin cancer development. In light of our data demonstrating distinct roles for COX-2 mediated PG expression in different cells during skin cancer progression, we add a third goal in this supplement application: We wish to ask """"""""Can COX-2 expression in a single cell type, from the endogenous Cox2 promoter, mediate/modulate DMBA/TPA or UV-B induced skin cancer?"""""""" For example, can """"""""endogenous"""""""" COX-2 expression from epithelial cells, without COX-2 expression in other cells, suffice for DMBA/TPA skin cancer induction? To answer this question we will develop Cox2 cell-restricted (Cox2Cr) mice in which the endogenous Cox2 gene is functionally silenced, unless a suppressing STOP sequence is removed by cell type-specific Cre excision.

Public Health Relevance

COX-2 inhibitors are still investigated as therapeutic and preventive agents for epithelial cancers, despite cardiovascular side effects. """"""""Down-stream"""""""" COX-2 pathway effectors (prostanoid synthases and receptors) have become targets for similar research. If we can pinpoint the cell type(s) in which COX-2 expression and the prostanoid effectors regulate cancer development, we may be able to target those steps with lower concentrations and less prolonged application of pharmacologic agents. We anticipate we will be able to define the critical cells for COX-2 cancer enhancement and suppression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA123055-03S1
Application #
7804210
Study Section
Special Emphasis Panel (ZRG1-OBT-B (95))
Program Officer
Mohla, Suresh
Project Start
2009-09-30
Project End
2011-09-29
Budget Start
2009-09-30
Budget End
2011-09-29
Support Year
3
Fiscal Year
2009
Total Cost
$200,973
Indirect Cost
Name
University of California Los Angeles
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Apostolova, Liana G; Di, Li Jie; Duffy, Erin L et al. (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord 37:315-26
Cherukuri, Durga P; Ishikawa, Tomo-O; Chun, Patrick et al. (2014) Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice. Mol Oncol 8:169-77
Li, Hua-Jung; Reinhardt, Ferenc; Herschman, Harvey R et al. (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2:840-55
Ishikawa, Tomo-o; Herschman, Harvey R (2011) Conditional bicistronic Cre reporter line expressing both firefly luciferase and ?-galactosidase. Mol Imaging Biol 13:284-92
Ishikawa, Tomo-O; Oshima, Masanobu; Herschman, Harvey R (2011) Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis 32:417-26
Ishikawa, Tomo-o; Jain, Naveen K; Herschman, Harvey R (2010) Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate. Mol Oncol 4:347-56
Ishikawa, Tomo-O; Herschman, Harvey R (2010) Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 31:729-36
Ishikawa, Tomo-O; Kumar, Indracanti Prem; Machado, Hidevaldo B et al. (2010) Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis. Mol Oncol 4:119-25
Papanicolaou, Kyriakos N; Streicher, John M; Ishikawa, Tomo-O et al. (2010) Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J Mol Cell Cardiol 49:196-209
Ishikawa, Tomo-O; Jain, Naveen; Herschman, Harvey R (2009) Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo. Biochem Biophys Res Commun 378:534-8

Showing the most recent 10 out of 12 publications